Abstract
The compounds reducing tumor cell viability and disrupting DNA topoisomerase reactions have been widely used in anticancer drug development. Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is a potent intercalating agent that interferes with nucleic acid processing through interaction with DNA topoisomerase II. Although ellipticine is a well-characterized compound, it is not a widely-accepted drug due to the adverse effects detected upon administration. We have previously reported two novel ellipticine derivatives, N-methyl-5-demethyl ellipticine (ET-1) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2) as potent compounds targeting DNA topoisomerase II. This study covers an extended synthesis, characterization, and activity data for five new salts of N-methyl 5-demetyl ellipticine (Z-1, Z-2, Z-4, Z-5 and Z-6) having several organic halides and their effects on human topoisomerase II enzymes. Moreover, combined in silico studies were conducted for better understanding of modes of action of studied molecules at the binding pocket of target. Our results showed that three of the derivatives (Z-1, Z-2, and Z-6) have considerable effect on the catalytic activity of human topoisomerase II implying the influence of alkyl groups added to the parental structure of ellipticine.
Similar content being viewed by others
References
Ashley RE, Osheroff N (2014) Natural products as topoisomerase II poisons: effects of thymoquinone on DNA cleavage mediated by human topoisomerase IIα. Chem Res Toxicol 27:787–793
Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369–413
Chikamori K, Grozav AG, Kozuki T, Grabowski D, Ganapathi R, Ganapathi MK (2010) DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr Cancer Drug Tar 10:758–777
Coban G, Zencir S, Zupkó I, Réthy B, Gunes HS, Topcu Z (2008) Synthesis and biological activity evaluation of 1H-benzimidazoles via mammalian DNA topoisomerase I and cytostaticity assays. Eur J Med Chem 44:2280–2285
Deane FM, O’Sullivan EC, Maguire AR, Gilbert J, Sakoff JA, McCluskey A, McCarthy FO (2013) Synthesis and evaluation of novel ellipticines as potential anti-cancer agents. Org Biomol Chem 1:1334–1344
Delgado JL, Hsieh CM, Chan NL, Hiasa H (2018) Topoisomerases as anticancer targets. Biochem J 475:373–398
Desmond molecular dynamics system, D.E.S.R., New York, NY, 2017.
Fosse P, Rene B, Charra M, Paoletti C, Saucier J (1992) Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives structure–activity relationship. Mol Pharm 42:590–595
Friesner R, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749
Garbett NC, Graves DE (2004) Extending nature’s leads: the anticancer agent ellipticine. Curr Med Chem Anticancer Agents 4:149–172
Gul HI, Cizmecioglu M, Zencir S, Gul M, Canturk P, Atalay M, Topcu Z (2009) Cytotoxic activity of 4’-hydroxychalcone derivatives against Jurkat cells and their effects on mammalian DNA topoisomerase I. J Enzym Inhib Med Chem 24:804–807
Hoover WG (1985) Canonical dynamics: equilibrium phase-space distributions. Phys Rev A 31:1695–1697
Iacopetta D, Rosano C, Puoci F, Parisi OI, Saturnino C, Caruso A et al. (2017) Multifaceted properties of 1,4dimethylcarbazoles: focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors. Eur J Pharm Sci 96:263–272
Ketron AC, Osheroff N (2014) Phytochemicals as anticancer and chemopreventive topoisomerase II poisons. Phytochem Rev 13:19–35
Kuo PL, Hsu YL, Chang CH, Lin CC (2005) The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223:293–301
Lichota A, Gwozdzinski K (2018) Anticancer activity of natural compounds from plant and marine environment. Int J Mol Sci 19:1–38
Martyna GJ (1994) Remarks on “Constant-temperature molecular dynamics with momentum conservation”. Phys Rev E 50:3234–3236
McClendon AK, Osheroff N (2007) DNA topoisomerase II, genotoxicity, and cancer. Mutat Res 623:83–97
Metacore/Metadrug platform, Clarivate Analytics (2019) https://portal.genego.com/
Miller CM, O’Sullivan EC, Devine KJ, McCarthy. CM (2012) Synthesis and biological evaluation of novel isoellipticine derivatives and salt. Org Biomol Chem 10:7912–7921
Moody DL, Dyba M, Kosakowska-Cholody T, Tarasova NI, Michejda CJ (2007) Synthesis and biological activity of 5-aza-ellipticine derivatives. Bioorg Med Chem Lett 17:2380–2384
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Rouëssé J, Spielmann M, Turpin F, Le Chevalier T, Azab M, Mondésir JM (1993) Phase II study of elliptinium acetate salvage treatment of advanced breast cancer. Eur J Cancer 29:856–859
Senarisoy M, Canturk P, Zencir S, Baran Y, Topcu Z (2013) Gossypol interferes with both type I and type II topoisomerase activities without generating strand breaks. Cell Biochem Biophys 66:199–204
Thompson D, Miller C, McCarthy FO (2008) Computer simulations reveal a novel nucleotide-type binding orientation for ellipticine-based anticancer c-kit kinase inhibitors. Biochemistry 47:10333–10344
Topcu Z (2001) DNA topoisomerases as targets for anticancer drugs. J Clin Pharm Ther 26:405–416
Topcu Z, Ozturk B, Kucukoglu O, Kilic E (2008) Inhibition of mammalian type I DNA topoisomerase by Helichrysum pamphylicum is correlated with the total antioxidant capacities of its individual flavonoids. Z Naturforsch C 63:69–74
Vann KR, Ekiz G, Zencir S, Bedir E, Topcu Z, Osheroff N (2016a) Effects of secondary metabolites from the fungus Septofusidium berolinense on DNA cleavage mediated by human topoisomerase IIα. Chem Res Toxicol 29:415–420
Vann KR, Ergun Y, Zencir S, Oncuoglu S, Osheroff N, Topcu Z (2016b) Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives. Bioorg Med Chem Lett 26:1809–1812
Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein-ligand docking using GOLD. Proteins 52:609–623
Wang JC (1971) Interaction between DNA and an Escherichia coli protein omega. J Mol Biol 55:523–533
Wendorff TJ, Schmidt BH, Heslop P, Austin CA, Berger JM (2012) The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol 424:109–124
Zupkó I, Molnár J, Réthy B, Minorics R, Frank E, Wölfling J et al. (2014) Anticancer and multidrug resistance-reversal effects of solanidine analogs synthetized from pregnadienolone acetate. Molecules 17:2061–2076
Acknowledgements
This study is supported by the grant of TUBITAK 115Z349 (PI; ZT).
Author contributions
MK, enzyme assays; VA, synthesis and characterization of test compounds; AK and IZ, mammalian cell viability assays; MZ and KS, in silico analyses; SD, in silico analyses and editing manuscript; HO, consultation and data analyses; YE, designing experiments, synthesis and characterization of test compounds, interpretation of data; SZ, designing experiments, enzyme assays, editing the manuscript; ZT, designed the project, enzyme assays, interpretation of data and writing manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
About this article
Cite this article
Kuskucu, M., Akyildiz, V., Kulmány, Á. et al. Structural modification of ellipticine derivatives with alkyl groups of varying length is influential on their effects on human DNA topoisomerase II: a combined experimental and computational study. Med Chem Res 29, 189–198 (2020). https://doi.org/10.1007/s00044-019-02472-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-019-02472-9